Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 7/20 | 0.40 |
| ▸ | FKBP1A | P62942 | 4/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | ACE | P12821 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5566752 | 0.83 | FKBP1A (0.39) | TMEM97FKBP1A | |
| SCHEMBL14600172 | 0.83 | TMEM97 (0.39) | TMEM97FKBP1AACE | |
| SCHEMBL13396941 | 0.81 | FKBP1A (0.46) | FKBP1AF2 | |
| SCHEMBL16124728 | 0.80 | FKBP1A (0.44) | FKBP1AF2ACEMEN1KMT2A | |
| SCHEMBL13396334 | 0.79 | KLK7 (0.48) | TMEM97FKBP1AGAAMEN1KMT2A | |
| SCHEMBL14600158 | 0.79 | TMEM97 (0.37) | TMEM97FKBP1AACE | |
| SCHEMBL14600154 | 0.78 | TMEM97 (0.38) | TMEM97FKBP1AACESPHK2SPHK1 | |
| SCHEMBL14600159 | 0.78 | TMEM97 (0.39) | TMEM97FKBP1AACE | |
| SCHEMBL14600149 | 0.76 | FKBP1A (0.38) | TMEM97FKBP1AACESPHK2MEN1 | |
| SCHEMBL14600129 | 0.76 | TMEM97 (0.36) | TMEM97FKBP1AACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7169805-B2 | Captopril derivatives | NICOX S.A. (FR) | 2007-01-30 | — | — | US | disclosed |
| EP-1626955-A1 | CAPTOPRIL DERIVATIVES | Nicox S.A. (FR) | 2006-02-22 | — | — | EP | disclosed |
| US-20040259808-A1 | Captopril derivatives | NICOX S.A. (FR) | 2004-12-23 | — | — | US | disclosed |
| WO-2004106300-A1 | CAPTOPRIL DERIVATIVES | NICOX S.A. (FR) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259808-A1 | Captopril derivatives | REN, ACE, NPPA | TMEM97 4399/4885FKBP1A 366/4885F2 2451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.